4 results
The objective of the trial is to confirm efficacy and a favorable benefit-risk ratio for BIBF 1120 in the treatment of IPF at the dose of 150 mg bid compared to placebo.
The aim of this extension trial is to provide BIBF 1120 treatment for all patients who have completed the 52 weeks treatment period and the follow up period in the phase III placebo controlled parent trial 1199.34, who may have experienced benefit…
2.1.1 Primary Objective:To evaluate the difference in the rates of graded pulmonary exacerbations in patients with bronchiectasis treated with inhaled mannitol compared with placebo control2.1.2 Secondary Objectives:EfficacyTo evaluate the…
to offer continuation of BIBF 1020 treatment for patients with IPF who have completed a prior clinical trial with that drug.establish the long term tolerability and safety profile of BIBF 1120 in IPF.